Skip to main content
Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc. — Investor Relations & Filings

Ticker · DYN ISIN · US26818M1080 US Manufacturing
Open in API
Filings indexed 627 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US DYN

About Dyne Therapeutics, Inc.

https://dyne-tx.com/

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies for individuals with genetically driven neuromuscular diseases. The company utilizes its proprietary FORCE™ platform, which is engineered to enable the targeted delivery of therapeutics to muscle tissue and address the root cause of disease. Dyne's clinical pipeline includes investigational treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). The company's primary objective is to deliver therapies that provide significant functional improvement for patients.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 92% confidence The document is a U.S. SEC Form 8-K “Current Report” disclosing a press release under Regulation FD and other non-financial events. It does not present full financial statements, earnings highlights, or detailed management discussion; rather it is a regulatory filing notifying the market of a material event. This aligns with the definition of Regulatory Filings (RNS).
2026-06-03 English
8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K “Current Report” under Item 2.02 “Results of Operations and Financial Condition,” stating that the company issued a press release announcing its financial results for the quarter ended March 31, 2026. This is the initial public summary announcement of quarterly results and not the full quarterly report itself, matching the definition of an Earnings Release. Q1 2026
2026-05-11 English
10-Q - Dyne Therapeutics, Inc. (0001818794) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
8-K - DYNE THERAPEUTICS, INC. (0001818794) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company issued a press release announcing financial results for the year ended December 31, 2025, and that the press release is furnished as an exhibit. The document itself does not contain the full financial results or detailed financial statements but rather references the press release. The length of the document is 3649 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and announces or furnishes a press release with financial results, it should be classified as an Earnings Release (ER).
2026-03-02 English
10-K - DYNE THERAPEUTICS, INC. (0001818794) (Filer)
Annual Report FY 2025
2026-03-02 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.